Results for this period
Full year21 May 2025 to 20 May 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company proceeded with increasing the proportion of stores offering prescription dispensing services, expanding its food category, converting stores to the “Food & Drug” format, opening new stores, and acquiring shares in and accepting business transfers from 5 food supermarket companies.
Not applicable (no matters to report in the notes on the going concern assumption)
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 21 May 2025 to 20 May 2026 |
| Net Sales | ¥566,865 million (YoY +13.0%) |
| Operating profit | ¥27,096 million (YoY +1.9%) |
| Ordinary income | ¥27,722 million (YoY +0.8%) |
| Profit attributable to owners of the parent | ¥17,133 million (YoY -3.7%) |
| Net income per share | ¥176.95 |
| Operating Margin | 4.8% |
| Equity ratio | End of the current fiscal period 34.3% / End of previous period 41.4% |
| Total assets | ¥410,937 million |
| Net assets | ¥141,038 million |
| Cash flows from operating activities | ¥37,321 million |
| Cash flows from investing activities | ¥-42,883 million |
| Cash flows from financing activities | ¥16,486 million |
| Cash and cash equivalents at end of period | ¥58,654 million |
| Full-year earnings forecast | Net Sales ¥640,000 million (YoY +12.9%) / Operating profit ¥32,000 million (YoY +18.1%) / Ordinary income ¥30,800 million (YoY +11.1%) / Net income ¥19,000 million (YoY +10.9%) |
| Annual Dividend Forecast | ¥56 → ¥64（+14.3%） |
| Payout ratio | 31.1% for the fiscal year ended May 2026; 32.0% forecast for the fiscal year ending May 2027 |
| Depreciation and amortization | ¥14,472 million |
| Impairment loss | ¥2,503 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥57 million, Gain on sale of investment securities ¥15 million / Extraordinary loss Loss on sale of fixed assets ¥1 million, Loss on Disposal of Fixed Assets ¥194 million, Impairment Losses ¥2,503 million, Impairment Loss on Investment Securities ¥408 million, Losses from natural disasters ¥123 million, Provision for disaster loss ¥11 million, Provision for store closure losses ¥468 million |
| Disclosure regarding the going concern assumption | Not applicable (no matters to report in the notes on the going concern assumption) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 4 / Company name 株式会社ミワ商店, 株式会社スポット, 株式会社魚栄商店, 株式会社魚齋藤 / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 95,616,980 |
| Treasury Shares at Period-End | 653,913 |
| Factors Behind Changes in Business Performance | The company proceeded with increasing the proportion of stores offering prescription dispensing services, expanding its food category, converting stores to the “Food & Drug” format, opening new stores, and acquiring shares in and accepting business transfers from 5 food supermarket companies. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company proceeded with increasing the proportion of stores offering prescription dispensing services, expanding its food category, converting stores to the “Food & Drug” format, opening new stores, and acquiring shares in and accepting business transfers from 5 food supermarket companies. The company recorded ¥2,503 million in impairment losses and ¥408 million in valuation losses on investment securities as extraordinary losses, among others.